Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study...
| Main Authors: | , , , , , |
|---|---|
| Format: | info:ar-repo/semantics/artículo |
| Language: | Inglés |
| Published: |
MDPI
2025
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/22085 https://www.mdpi.com/1999-4915/17/4/476 https://doi.org/10.3390/v17040476 |
| _version_ | 1855038514315395072 |
|---|---|
| author | Garanzini, Debora Patricia Micucci, Matías Torres Lopez, Annalies Perez, Oscar Calamante, Gabriela Del Medico Zajac, Maria Paula |
| author_browse | Calamante, Gabriela Del Medico Zajac, Maria Paula Garanzini, Debora Patricia Micucci, Matías Perez, Oscar Torres Lopez, Annalies |
| author_facet | Garanzini, Debora Patricia Micucci, Matías Torres Lopez, Annalies Perez, Oscar Calamante, Gabriela Del Medico Zajac, Maria Paula |
| author_sort | Garanzini, Debora Patricia |
| collection | INTA Digital |
| description | Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals. |
| format | info:ar-repo/semantics/artículo |
| id | INTA22085 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI |
| publisherStr | MDPI |
| record_format | dspace |
| spelling | INTA220852025-04-28T15:10:35Z Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein Garanzini, Debora Patricia Micucci, Matías Torres Lopez, Annalies Perez, Oscar Calamante, Gabriela Del Medico Zajac, Maria Paula Adenoviridae Vectors Glycoproteins Rabies Vaccines Vectores Glicoproteínas Rabia Vacuna Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals. Instituto de Biotecnología Fil: Garanzini, Debora Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina Fil: Garanzini, Debora Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Micucci, Matías. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina Fil: Torres Lopez, Annalies. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina Fil: Torres Lopez, Annalies. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Perez, Oscar. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina Fil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina Fil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina 2025-04-28T15:04:05Z 2025-04-28T15:04:05Z 2025-04 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/22085 https://www.mdpi.com/1999-4915/17/4/476 1999-4915 https://doi.org/10.3390/v17040476 eng info:eu-repograntAgreement/INTA/2023-PD-L06-I116, Implementación de tecnologías y nuevas estrategias preventivas y terapéuticas para el desarrollo sustentable y eficiente de la producción animal en el marco de Una Salud info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf MDPI Viruses 17 (4) : 476 (April 2025) |
| spellingShingle | Adenoviridae Vectors Glycoproteins Rabies Vaccines Vectores Glicoproteínas Rabia Vacuna Garanzini, Debora Patricia Micucci, Matías Torres Lopez, Annalies Perez, Oscar Calamante, Gabriela Del Medico Zajac, Maria Paula Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title | Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title_full | Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title_fullStr | Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title_full_unstemmed | Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title_short | Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein |
| title_sort | protection against rabies induced by the non replicative viral vectors mva and ad5 expressing rabies glycoprotein |
| topic | Adenoviridae Vectors Glycoproteins Rabies Vaccines Vectores Glicoproteínas Rabia Vacuna |
| url | http://hdl.handle.net/20.500.12123/22085 https://www.mdpi.com/1999-4915/17/4/476 https://doi.org/10.3390/v17040476 |
| work_keys_str_mv | AT garanzinideborapatricia protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein AT micuccimatias protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein AT torreslopezannalies protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein AT perezoscar protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein AT calamantegabriela protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein AT delmedicozajacmariapaula protectionagainstrabiesinducedbythenonreplicativeviralvectorsmvaandad5expressingrabiesglycoprotein |